Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Stomach Neoplasms 7Carcinoma, Non-Small-Cell Lung 7Neoplasms 6Colorectal Neoplasms 5Neoplasm Metastasis 3Adenocarcinoma 3Urinary Bladder Neoplasms 2Melanoma 2Esophageal Neoplasms 2Colonic Neoplasms 2Carcinoma, Renal Cell 2Carcinoma, Hepatocellular 2Breast Neoplasms 2Biliary Tract Neoplasms 2Urethral Neoplasms 1Ureteral Neoplasms 1Solid Tumors 1Solid Tumor 1Sarcoma, Alveolar Soft Part 1Recurrence 1Rectal Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasms by Site 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Head and Neck Neoplasms 1Gastrointestinal Neoplasms 1Fallopian Tube Neoplasms 1Digestive System Neoplasms 1

Interventions

Cyclophosphamide 41fludarabine 31Dexamethasone 27venetoclax 24Cytarabine 22Rituximab 16pembrolizumab 15fludarabine phosphate 14Filgrastim 12Etoposide 12Lenalidomide 11Vincristine 10Gemcitabine 10Azacitidine 10pomalidomide 9Interleukin-2 9Granulocyte Colony-Stimulating Factor 9Doxorubicin 9Calcium Dobesilate 9carfilzomib 8Topotecan 8Nivolumab 8Methotrexate 8Everolimus 8Decitabine 8Bortezomib 8Melphalan 7Cisplatin 7Vorinostat 6Injections 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Recurrence × Ramucirumab × Clear all
NCT02564198 2021-08-17

A Study of Ramucirumab (LY3009806) in Children With Refractory Solid Tumors

Eli Lilly and Company

Phase 1 Completed
29 enrolled 12 charts
CNS

Neoplasms, Recurrence, Central Nervous System Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡